Table 2 Distribution of comorbidities and medications used within the study groups
Senior orienteering athletes (n = 27) | General older adults (n = 22) | Older adults with GI symptoms (n = 24) | |
|---|---|---|---|
Comorbidities | % | % | % |
Cardiovascular diseases | 14.8 | 18.2 | 50.0 |
Gut symptoms | 11.1 | 22.7 | 100.0 |
Psychological & neurodegenerative morbidities | 3.7 | 13.6 | 8.3 |
Others (respiratory tract, urinary tract, musculo-skeletal, eyes) | 25.9 | 22.7 | 33.3 |
Medications | % | % | % |
Cardiovascular agents | 25.9 | 18.2 | 50.0 |
-Blood pressure lowering substances | 18.5 | 18.2 | 37.5 |
-Lipid-lowering medications | - 18.5 | - 0.0 | - 12.5 |
-Anti-coagulants | - 11.1 | - 0.0 | - 20.8 |
-Others | - 3.7 | - 0.0 | - 12.5 |
Anti-inflammatory agents (NSAID, cortisone) | 0 | 0 | 4.2 |
Gut motility regulating substances | 3.7 | 18.2 | 29.2 |
-Anti-constipation medicine | - 0.0 | - 13.6 | - 12.5 |
-Anti-diarrheal medicine | |||
-Other GI regulators (probiotics, fibres) | - 7.4 | - 4.5 | - 4.2 |
-Proton pump inhibitors (PPI) | - 0.0 | - 0.0 | - 4.2 |
Antibiotics | 0 | 4.5 | 16.7 |
-Neurology drugs | 3.7 | 13.6 | 12.5 |
-Anti-depressants | - 3.7 | - 13.6 | - 0.0 |
-Hypnotics | - 0.0 | - 0.0 | - 4.2 |
-Dopamine-agonists | - 0.0 | - 4.5 | - 4.2 |
-Cholinesterase-inhibitors | - 0.0 | - 0.0 | - 4.2 |
Others | 18.5 | 27.3 | 29.2 |
Polypharmacy (5 or more drugs) | 3.7 | 0 | 12.5 |
Other GI regulators (probiotics, fibres etc.) | 0 | 4.5 | 8.3 |